Abstracts tagged "Behcet’s syndrome and vasculitis"

Abstract Number: 768 • 2019 ACR/ARP Annual Meeting
Angiographic Patterns and Changes in Arterial Lesions in Patients with Behcet’s Disease
Su Jin Choi¹, So Hye Nam ¹, Jung Sun Lee ¹, Doo-Ho Lim ², Ji Seon Oh ³, Seokchan Hong ¹, Yong-Gil Kim ¹, Chang-Keun Lee ¹ and Bin Yoo ¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, Republic of Korea, ³Department of Biomedical Informatics, Asan Medical Center, Seoul, Korea, Seoul, Republic of Korea
Background/Purpose: Arterial involvement is a manifestation of systemic vasculitis in Behçet’s disease (BD). Changes to BD arterial lesions over time can help predict patient prognosis.…
Abstract Number: 1693 • 2019 ACR/ARP Annual Meeting
Biological Therapy in Neurobehçet: Multicenter Study of 31 Patients
Iñigo Gonzalez-Mazon¹, Lara Sanchez-Bilbao ², Jose Luis Martín-Varillas ², Belén Atienza-Mateo ², Vanesa Calvo Río ², Santos Castañeda ³, Esther Vicente-Rabaneda ⁴, Olga Maiz ⁵, ana blanco ⁵, Clara Moriano ⁶, Elvira Díez ⁶, JL Andreu ⁷, Concepción Delgado-Beltrán ⁸, Marta Loredo-Martinez ⁸, Javier Narváez ⁹, Angel Ramos-Calvo ¹⁰, Francisca Sivera ¹¹, E. Raya ¹², Norberto Ortego Centeno ¹², Jose luis callejas rubio ¹², Anahy Brandy-Garcia ¹³, Alejandro Olivé-Marqués ¹⁴, Sabela Fernández ¹⁵, Ricardo Gómez De La Torre ¹⁶, Iñaki Torre-Salaberri ¹⁷, Julio Sanchez ¹⁸, A. Urruticoechea-Arana ¹⁹, Eva salgado-Pérez ²⁰, Rafael Melero ²¹, Olga Martinez ²², Susana Romero-Yuste ²³, Miguel A Gonzalez-Gay ² and Ricardo Blanco ², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Rheumatology, Hospital Universitario La Princesa, Madrid, Madrid, Spain, ⁴Rheumatology Department, Hospital Universitario La Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario Donostia, san sebastian, Pais Vasco, Spain, ⁶Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁷HU Puerta del Hierro, Madrid, ⁸H. Clinico Lozano Blesa Zaragoza, Zaragoza, Aragon, Spain, ⁹Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, ¹⁰Rheumatology, Complejo Hospitalario de Soria, soria, Castilla y Leon, Spain, ¹¹Hospital General Universitario de Elda, Elda, Spain, ¹²Hospital San Cecilio, Granada, Andalucia, Spain, ¹³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, ¹⁵Hospital Universitario San Agustín, Avilés, Asturias, Spain, ¹⁶Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain, Oviedo, Spain, ¹⁷BASURTO UNIVERSITY HOSPITAL, Bilbao, Spain, ¹⁸H. 12 de Octubre, Madrid, Spain, ¹⁹HU Can Misses, Ibiza, Spain, ²⁰Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, ²¹Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ²²Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²³Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain
Background/Purpose: Behçet's disease (BD) is a variable vessel vasculitis and typically presents with mucocutaneous involvement. However, any organ can be affected, being the neurological affectation…
Abstract Number: 1803 • 2018 ACR/ARHP Annual Meeting
Assessment of Severity and Risk Factors of Post-Thrombotic Syndrome in Vascular Behçet Disease: Muticentered Retrospective Study
Aysun Aksoy¹, Seda Çolak², Burcu Yagız³, Belkıs Nihan Coşkun⁴, Ahmet Omma⁵, Naile Bolca⁶, Rabia Ergelen⁷, Haner Direskeneli⁸ and Fatma Alibaz-Oner¹, ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Numune Training and Research Hospital, ankara, Turkey, ³Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ⁴Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁵Numune Training and Research Hospital, ankara, Turkey, ⁶Radiology, Uludag University, School of Medicine, Bursa, Turkey, ⁷Marmara University School of Medicine, Radiology, ISTANBUL, Turkey, ⁸Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Vascular involvement is seen in about one third of patients with Behçet Disease(BD). DVT(deep venous thrombosis) is the most common form of vascular Behçet…
Abstract Number: 2733 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment Outcomes of Patients with Behçet’s Disease and Vascular Involvement
In Young Kim¹, Yeong Hee Eun², Ji young Chai³, Hyungjin Kim¹, Jaejoon Lee¹, Eun-Mi Koh¹, Duk-Kyung Kim⁴ and Hoon-Suk Cha¹, ¹Department of Medicine,Division of Rheumatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Medicine,Division of Rheumatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, MN, Korea, Republic of (South), ³Department of Rheumatology, Bundang Jesaeng Hospital, Seongnam, Korea, Republic of (South), ⁴Department of Medicine,Division of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: The international Chapel Hill Consensus Conference (CHCC) categorized Behçet’s disease (BD) as variable vessel vasculitis, which was defined as vasculitis that can affect vessels…
Abstract Number: 2960 • 2016 ACR/ARHP Annual Meeting
Increased Post-Thrombotic Syndrome Is Unassociated with Anticoagulant Use in Vascular Behcet’s Disease
Fatma Alibaz-Oner¹, Belgin Aldag¹, Mustafa Aldag², Ali Ugur Unal¹, Aydan Mutiş³, Tayfur Toptas⁴, Tulin Ergun⁵ and Haner Direskeneli⁶, ¹Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²Dr.Siyami Ersek Cardiovascular Surgery Hospital,, Istanbul, Turkey, ³Marmara University, School of Medicine, Rheumatology, ISTANBUL, Turkey, ⁴Marmara University, School of Medicine, Hematology, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, ⁶Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Deep venous thrombosis (DVT) is the most common form of vascular involvement in Behcet’s disease (BD). Chronic post-thrombotic syndrome (PTS) develops frequently in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].